^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yonsa (abiraterone acetate)

    i
    Other names: AAFP, abiraterone acetate fine particle, submicron abiraterone acetate
    Associations

    News

    Trials
    Company:
    Churchill Pharma, Sun Pharma
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    16d
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1314, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    2ms
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1314, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Dec 2030 --> May 2028
    Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    2ms
    Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. (clinicaltrials.gov)
    P1, N=50, Terminated, University of Chicago | Trial completion date: Nov 2025 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Nov 2024; Closed by PI due to not meeting primary endpoint
    Trial completion date • Trial termination • Trial primary completion date
    |
    abiraterone acetate • Yonsa (abiraterone acetate)
    2ms
    OMAHA1: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1310, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    3ms
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1500, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    5ms
    OMAHA1: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    6ms
    Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer (clinicaltrials.gov)
    P2, N=110, Recruiting, Mayo Clinic | N=57 --> 110
    Enrollment change
    |
    abiraterone acetate • Yonsa (abiraterone acetate)
    6ms
    A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces (clinicaltrials.gov)
    P=N/A, N=2313, Completed, Pfizer | N=1000 --> 2313
    Enrollment change
    |
    Xtandi (enzalutamide) • abiraterone acetate • apalutamide • Yonsa (abiraterone acetate)
    6ms
    A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=2731, Completed, Pfizer | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Xtandi (enzalutamide) • abiraterone acetate • Yonsa (abiraterone acetate)
    7ms
    A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (clinicaltrials.gov)
    P=N/A, N=3017, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    Xtandi (enzalutamide) • abiraterone acetate • apalutamide • Yonsa (abiraterone acetate)
    9ms
    NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    abiraterone acetate • apalutamide • Yonsa (abiraterone acetate)
    10ms
    REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial (clinicaltrials.gov)
    P3, N=72, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • bicalutamide • Orgovyx (relugolix) • leuprolide acetate for depot suspension • Yonsa (abiraterone acetate)